Characterization of pigs transgenic for human decay-accelerating factor

Transplantation

Volumn 64, Issue 10, 1997, Pages 1383-1392

  Cozzi, Emanuele ^a,b,c,e   Tucker, Alexander W ^c   Langford, Gillian A ^c   Pino Chavez, Gilda ^c   Wright, Les ^a   O'Connell, Mary Jane ^d   Young, Vincent J ^c   Lancaster, Richard ^c   McLaughlin, Megan ^c   Hunt, Kathy ^c   Bordin, Maria C ^b   White, David J G ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c Imutran Ltd   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Douglas House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; NONHUMAN; ORGAN DONOR; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SWINE; TRANSGENE; XENOTRANSPLANTATION;

EID: 0030831579     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199711270-00002     Document Type: Article

References (47)

1. Dorling A, Lechler R. Clinical xenotransplantation of solid organs. Lancet 1997; 349: 867.
2. Cooper DKC. Xenografting: how great is the clinical need? Xeno 1993; 1: 25.
3. Cooper DKC, Ye Y, Rolf JLL, Zuhdi N. The Pig as potential organ donor for man. In: Cooper DKC, Kemp E, Reemtsma K, White DJG, eds. Xeno-transplantation: the transplantation of organs and tissues between species. Berlin: Springer-Verlag, 1991: 481.
4. Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964.
5. Platt JL, Bach FH. The barrier to xenotransplantation. Transplantation 1991; 52: 937.
6. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanisms of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140(5): 1157.
7. Zhao Z, Termignon JL, Cardoso J, et al. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination: in vitro analysis of complement activation. Transplantation 1994; 57: 245.
8. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
9. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480.
10. Bach FH, Blakely ML, Van Der Werf M, et al. Discordant xenografting: a working model of problems and issues. Xeno 1993; 1: 8.
11. Auchincloss H Jr. Xenogeneic transplantation: a review. Transplantation 1988; 46: 1.
12. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 1991; 52: 530.
13. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
14. Johnston PS, Wang MW, Lim SM, Wright LJ, White DJ. Discordant xenograft rejection in an antibody-free model. Transplantation 1992; 54: 573.
15. Pruitt SK, Kirk DA, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
16. Kobayashi T, Neethling FA, Koren E, et al. In vitro and in vivo investigation of anticomplement agents FUT-175 and K75COOH, in the prevention of hyperacute rejection following discordant xenotransplantation in a nonhuman primate model. Transplant Proc 1996; 28: 604.
17. Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 1194.
18. Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 1995; 60: 1282.
19. Langford GA, Yannoutsos N, Cozzi E, et al. Production of pigs transgenic for human decay accelerating factor. Transplant Proc 1994; 26: 1400.
20. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423.
21. Yannoutsos N, Langford GA, Cozzi E, et al. Production of pigs transgenic for human regulators of complement activation. Transplant Proc 1995; 27: 324.
22. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
23. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay accelerating factor, in transgenic pigs: a potential approach for preventing xenograft rejection. Transplantation 1995; 9: 1325.
24. Kinoshita T, Medof ME, Silber R, Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985; 162: 75.
25. Spring FA, Judson PA, Daniels GL, Parsons SF, Mallinson G, Anstee DJ. A human cell surface glycoprotein that carries Cromer related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology 1987; 62: 307.
26. Tate CG, Uchikawa M, Tanner MJ, et al. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype. Biochem J 1989; 261: 489.
27. Zweig SE, Shevach EM. Production and properties of monoclonal antibodies to guinea pig Ia antigens. Methods Enzymol 1983; 92: 66.
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680.
29. Carrington CA, Richards AC, Tucker AW, Peters AL, White DJG. A line of transgenic pigs in which the expression of human decay-accelerating factor by endothelial cells is increased in the presence of inflammatory stimuli. Xenotransplantation 1996; 3: 87.
30. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114.
31. Lachmann PJ, Oldroyd RG, Milstein C, Wright BW. Three rat monoclonal antibodies to human C3. Immunology 1980; 41: 503.
32. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550.
33. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute rejection in a swine to primate model. Transplantation 1991; 52: 214.
34. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404.
35. Makowka L, Cramer DV, Hoffman A, et al. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995; 59: 1654.
36. Stafford HA, Tykocinski ML, Lublin DM, et al. Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci USA 1988; 85: 880.
37. Lublin DM, Krsek-Staples J, Pangburn MK, Atkinson JP. Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J Immunol 1986; 137: 1629.
38. Velander WH, Johnson JL, Page RL, et al. High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci USA 1992; 89: 12003.
39. Coyne KE, Hall SE, Thompson ES, et al. Mapping of epitopes, glycosylation sites and complement regulatory domains in human decay accelerating factor. J Immunol 1992; 149: 2906.
40. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989; 7: 35.
41. Cozzi E, Yannoutsos N, Langford GA, et al. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xeno-transplantation: the transplantation of organs and tissues between species, 2nd edition. Berlin: Springer-Verlag, 1997: 665.
42. Kaplon RJ, Platt JL, Kwiatkowski PA, et al. Absence of hyperacute rejection in pig-to-primate orthotopic pulmonary xenografts. Transplantation 1995; 59: 410.
43. Hammer RE, Pursel VG, Rexroad CE, et al. Production of transgenic rabbits, sheep and pigs by microinjection. Nature 1985; 315: 680.
44. Miller KF, Bolt DJ, Pursel VG, et al. Expression of human or bovine growth hormone gene with a mouse metallothionein-1 promoter in transgenic swine alters the secretion of porcine growth hormone and insulin-like growth factor-I. J Endocrinol 1989; 120: 481.
45. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation 1996; 62: 303.
46. Bach FH, Robson SC, Wrighton CJ, Stuhlmeier K, Ferran C, Winkler H. Genetic engineering of endothelial cells to ameliorate xenograft rejection. Clin Transplantation 1996; 10: 124.
47. White DJG, Langford GA, Cozzi E, Young VJ. Production of pigs transgenic for human DAF: a strategy for xenotransplantation. Xenotransplantation 1995; 2: 213.